DN1508052

DN1508052 is an orally bioavailable, small molecule agonist of Toll-like receptor 8 (TLR8) being developed by Shanghai De Novo Pharmatech for the treatment of advanced solid tumors. TLR8 is an endosomal receptor primarily expressed in myeloid cells, such as monocytes, macrophages, and myeloid dendritic cells. Activation of TLR8 by DN1508052 triggers the NF-κB signaling pathway, leading to the secretion of Th1-type cytokines including IL-12, TNF-α, and IFN-γ. This pro-inflammatory response reverses immunosuppression within the tumor microenvironment and promotes the activation of natural killer (NK) cells and tumor-specific cytotoxic T lymphocytes. DN1508052 is currently undergoing Phase I clinical evaluation to determine its safety, pharmacokinetics, and preliminary antitumor activity in patients with refractory solid malignancies.